Eris Lifesciences Ltd (ERIS) Price & Analysis

Compare

0 Followers

ERIS Stock Chart & Stats

₹1530.85

₹7.70(0.59%)

At close: Jan 09 4:00 PM EST

₹1530.85

₹7.70(0.59%)

Day’s Range― - ―

52-Week Range₹1,140.00 - ₹1,909.55

Previous CloseN/A

Volume91.31K

Average Volume (3M)2.07K

Market Cap

₹183.06B

Enterprise Value₹204.28B

Total Cash (Recent Filing)₹2.05B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)42.4

Beta0.66

Next Earnings

May 26, 2026

EPS Estimate

11.7

Next Dividend Ex-DateN/A

Dividend Yield0.47%

Share Statistics

EPS (TTM)7.30

Shares Outstanding136,216,890

10 Day Avg. Volume1,915

30 Day Avg. Volume2,071

Financial Highlights & Ratios

PEG Ratio-5.23

Price to Book (P/B)6.64

Price to Sales (P/S)6.58

P/FCF Ratio20.82

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Margin GrowthConsistent revenue expansion and robust gross margins indicate durable demand for Eris’s branded portfolio and efficient cost control. Sustained top-line momentum and healthy operating margins support reinvestment in brands and sales force, underpinning multi-quarter profit resilience.

Strong Operating Cash Flow And Improving FCFGrowing operating cash generation and improving free cash flow reflect solid core profitability and disciplined capex. Reliable cash conversion enhances funding for marketing, acquisitions, and debt servicing, increasing financial flexibility over several quarters to years.

Branded Chronic-therapy Business ModelA concentrated portfolio in chronic/lifestyle therapies yields recurring prescriptions and stable demand, benefiting from physician loyalty and long treatment durations. The branded, physician-facing model supports pricing power and repeat sales, strengthening long-term revenue visibility.

Bears Say

Decreasing Cash BalancesA declining cash balance reduces short-term liquidity buffers and limits optionality for opportunistic investments or margin cushions. Over a multi-quarter horizon, weaker cash reserves can constrain flexibility to fund marketing, M&A, or absorb unexpected operational shocks.

Free Cash Flow VolatilityMaterial swings in free cash flow suggest earnings-to-cash conversion is not fully stable, exposing the company to timing risks from working capital or capex. Persisting FCF volatility can hinder consistent reinvestment and increase reliance on external financing during weaker periods.

Exposure To Price-control & Regulatory RiskConcentration in the Indian branded market subjects margins to government price controls and regulatory changes. Structural policy shifts or price caps on covered molecules could compress profitability and reduce pricing flexibility across multiple quarters to years.

Eris Lifesciences Ltd News

Eris Lifesciences Posts Analyst Call Transcript for Q3 FY26

Eris Lifesciences Ltd ( ($IN:ERIS) ) has shared an announcement. Eris Lifesciences Ltd has announced that the transcript...

6h ago

ERIS

Eris Lifesciences Raises Stake to Make Swiss Parenterals Wholly Owned Unit via Preferential Share Allotment

Eris Lifesciences Ltd ( ($IN:ERIS) ) has shared an update. Eris Lifesciences has allotted 2,306,372 fully paid equity...

1M ago

ERIS

Eris Lifesciences Announces Postal Ballot Notice Dispatch

An announcement from Eris Lifesciences Ltd ( ($IN:ERIS) ) is now available. Eris Lifesciences Limited has announced the...

3M ago

ERIS

Eris Lifesciences Initiates Postal Ballot for Shareholder Resolutions

The latest update is out from Eris Lifesciences Ltd ( ($IN:ERIS) ). Eris Lifesciences Ltd has announced a...

3M ago

ERIS

Eris Lifesciences Acquires 30% Stake in Swiss Parenterals

Eris Lifesciences Ltd ( ($IN:ERIS) ) just unveiled an update. Eris Lifesciences Ltd announced the acquisition of 30%...

3M ago

ERIS

Eris Lifesciences Expands Stake in Swiss Parenterals

Eris Lifesciences Ltd ( ($IN:ERIS) ) has shared an update. Eris Lifesciences Ltd’s board has approved the acquisition...

3M ago

ERIS

Eris Lifesciences Announces Investor Call to Discuss Financial Results

The latest update is out from Eris Lifesciences Ltd ( ($IN:ERIS) ). Eris Lifesciences Ltd has announced a...

4M ago

ERIS

Eris Lifesciences Schedules Investor Meeting with Mirae Asset

The latest announcement is out from Eris Lifesciences Ltd ( ($IN:ERIS) ). Eris Lifesciences Ltd has announced a...

11M ago

ERIS

ERIS FAQ

What was Eris Lifesciences Ltd’s price range in the past 12 months?

Eris Lifesciences Ltd lowest stock price was ₹1140.00 and its highest was ₹1909.55 in the past 12 months.

What is Eris Lifesciences Ltd’s market cap?

Eris Lifesciences Ltd’s market cap is ₹183.06B.

When is Eris Lifesciences Ltd’s upcoming earnings report date?

Eris Lifesciences Ltd’s upcoming earnings report date is May 26, 2026 which is in 95 days.

How were Eris Lifesciences Ltd’s earnings last quarter?

Eris Lifesciences Ltd released its earnings results on Feb 13, 2026. The company reported ₹7.3 earnings per share for the quarter, missing the consensus estimate of ₹9.625 by -₹2.325.

Is Eris Lifesciences Ltd overvalued?

According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Eris Lifesciences Ltd pay dividends?

Eris Lifesciences Ltd pays a Annually dividend of ₹7.35 which represents an annual dividend yield of 0.47%. See more information on Eris Lifesciences Ltd dividends here

What is Eris Lifesciences Ltd’s EPS estimate?

Eris Lifesciences Ltd’s EPS estimate is 11.7.

How many shares outstanding does Eris Lifesciences Ltd have?

Eris Lifesciences Ltd has 136,216,890 shares outstanding.

What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?

Eris Lifesciences Ltd reported an EPS of ₹7.3 in its last earnings report, missing expectations of ₹9.625. Following the earnings report the stock price went down -6.38%.

Which hedge fund is a major shareholder of Eris Lifesciences Ltd?

Currently, no hedge funds are holding shares in IN:ERIS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Eris Lifesciences Ltd

Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.